Article Text


Novel bivalent vectored vaccine for control of myxomatosis and rabbit haemorrhagic disease
  1. N. Spibey, BSc. PhD1,
  2. V. J. McCabe, BSc. PhD1,
  3. N. M. Greenwood, MPhil1,
  4. S. C. Jack, BSc. PhD1,
  5. D. Sutton, BVetMed1 and
  6. L. van der Waart, BSc2
  1. MSD Animal Health, Milton Keynes, UK
  2. MSD Animal Health, Boxmeer, The Netherlands
  1. E-mail for correspondence norman.spibey{at}

A novel, recombinant myxoma virus-rabbit haemorrhagic disease virus (RHDV) vaccine has been developed for the prevention of myxomatosis and rabbit haemorrhagic disease (RHD). A number of laboratory studies are described illustrating the safety and efficacy of the vaccine following subcutaneous administration in laboratory rabbits from four weeks of age onwards. In these studies, both vaccinated and unvaccinated control rabbits were challenged using pathogenic strains of RHD and myxoma viruses, and 100 per cent of the vaccinated rabbits were protected against both myxomatosis and RHD.

This paper is freely available online under the BMJ Journals unlocked scheme, see

Statistics from


  • Provenance not commissioned; externally peer reviewed

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.